Compare Eli Lilly And Co (LLY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sony Group Corp — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Eli Lilly And Co is far larger — about 7.6× Sony Group Corp's market cap, and Sony Group Corp pays the higher dividend (0.66%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Sony Group Corp for 96 Days on average.
| LLY | SONY | |
|---|---|---|
Market Cap | $1.04T | $136.87B |
Volume | 3,064,878 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $1.28K | $30.26 |
52-Week Low | $799.57 | $19.32 |
Typical Hold Time | 93 Days | 96 Days |
Enterprise Value | $1.09T | $134.77B |
Dividend Yield | 0.59% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Sony trades at $24.12, up 2.55% today, with a bullish technical outlook supported by moving averages. The company reported mixed quarterly results with two beats and one miss, while full-year 2025 showed strong revenue of $12.96T and net income of $1.14T. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations, though 2026 projections indicate potential profitability challenges with negative net income margins.
Sony presents a compelling value opportunity with reasonable valuation metrics (P/E 20.34, P/S 1.79) and strong cash flow generation, but faces headwinds from projected 2026 profitability decline. The entertainment and technology conglomerate benefits from diverse revenue streams and intellectual property strength, though investors should monitor execution risks amid competitive pressures and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
